

References to ESBL action plan

- 1 Rodriguez-Bano J, Navarro MD, Romero L, Martinez-Martinez L, Muniain MA, Perea EJ, et al. Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase-producing *Escherichia coli* in nonhospitalized patients. *J Clin Microbiol* 2004;42(3):1089-94.
- 2 Ena J, Arjona F, Martinez-Peinado C, Lopez-Perezagua Mdel M, Amador C. Epidemiology of urinary tract infections caused by extended-spectrum betalactamase-producing *Escherichia coli*. *Urology* 2006;68(6):1169-74.
- 3 Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. *Clin Microbiol Rev* 2005;18(4):657-86.
- 4 Jacoby GA, Walsh KE, Walker VJ. Identification of extended-spectrum, AmpC, and carbapenem-hydrolyzing beta-lactamases in *Escherichia coli* and *Klebsiella pneumoniae* by disk tests. *J Clin Microbiol* 2006;44(6):1971-6.
- 5 Giske CG, Haldorsen B, Lundblad EW, Aasnaes B, Bylund L, Phion H, et al. Phenotypic detection of AmpC: Comparison of Etest AmpC strips and disk synergy assays with cloxacillin, boronic acid and EDTA. In: European Congress of Clinical Microbiology and Infectious Diseases; 2007; Munich; 2007.
- 6 Walsh TR, Toleman MA, Poirel L, Nordmann P. Metallo-beta-lactamases: the quiet before the storm? *Clin Microbiol Rev* 2005;18(2):306-25.
- 7 Poirel L, Nordmann P. Carbapenem resistance in *Acinetobacter baumannii*: mechanisms and epidemiology. *Clin Microbiol Infect* 2006;12(9):826-36.
- 8 Livermore DM, Canton R, Gniadkowski M, Nordmann P, Rossolini GM, Arlet G, et al. CTX-M: changing the face of ESBLs in Europe. *J Antimicrob Chemother* 2007;59(2):165-74.
- 9 Valverde A, Coque TM, Sanchez-Moreno MP, Rollan A, Baquero F, Canton R. Dramatic increase in prevalence of fecal carriage of extended-spectrum betalactamase-producing *Enterobacteriaceae* during nonoutbreak situations in Spain. *J Clin Microbiol* 2004;42(10):4769-75.
- 10 Oteo J, Navarro C, Cercenado E, Delgado-Iribarren A, Wilhelmi I, Orden B, et al. Spread of *Escherichia coli* strains with high-level cefotaxime and ceftazidime resistance between the community, long-term care facilities, and hospital institutions. *J Clin Microbiol* 2006;44(7):2359-66.
- 11 Mesa RJ, Blanc V, Blanch AR, Cortes P, Gonzalez JJ, Lavilla S, et al. Extendedspectrum beta-lactamase-producing *Enterobacteriaceae* in different environments (humans, food, animal farms and sewage). *J Antimicrob Chemother* 2006;58(1):211-5.
- 12 Fang H, Lundberg C, Olsson-Liljequist B, Hedin G, Lindback E, Rosenberg A, et al. Molecular epidemiological analysis of *Escherichia coli* isolates producing extended-spectrum beta-lactamases for identification of nosocomial outbreaks in Stockholm, Sweden. *J Clin Microbiol* 2004;42(12):5917-20.
- 13 Swedres. Report on Swedish Antibiotic Utilisation and Resistance in Human Medicine: Smittskyddsinstitutet; 2006.
- 14 Birkett CI, Ludlam HA, Woodford N, Brown DF, Brown NM, Roberts MT, et al. Real-time TaqMan PCR for rapid detection and typing of genes encoding CTX-M extended-spectrum beta-lactamases. *J Med Microbiol* 2007;56(Pt 1):52-5.

- 15 Chia JH, Chu C, Su LH, Chiu CH, Kuo AJ, Sun CF, et al. Development of a multiplex PCR and SHV melting-curve mutation detection system for detection of some SHV and CTX-M beta-lactamases of *Escherichia coli*, *Klebsiella pneumoniae*, and *Enterobacter cloacae* in Taiwan. *J Clin Microbiol* 2005;43(9):4486-91.
- 16 Naas T, Oxacelay C, Nordmann P. Identification of CTX-M-type extended-spectrum-beta-lactamase genes using real-time PCR and pyrosequencing. *Antimicrob Agents Chemother* 2007;51(1):223-30.
- 17 Pitout JD, Hossain A, Hanson ND. Phenotypic and molecular detection of CTX-M-beta-lactamases produced by *Escherichia coli* and *Klebsiella* spp. *J Clin Microbiol* 2004;42(12):5715-21.
- 18 Stepanova M, Nikulin A, Sukhorukova M, Edelstein M. Epidemiological surveillance and characterisation of TEM- SHV- and CTX-M-type ESBLs in Russian nosocomial strains of *Enterobacteriaceae* using real-time PCR and melting-curve analysis techniques. In: *European Congress of Clinical Microbiology and Infectious Diseases; 2007; Munich; 2007.*
- 19 Wilson G, McCabe D. The use of antibiotic-containing agars for the isolation of extended-spectrum beta-lactamase-producing organisms in intensive care units. *Clin Microbiol Infect* 2007;13(4):451-3.
- 20 Glupczynski Y, Berhin C, Bauraing C, Bogaerts P. Evaluation of a new selective chromogenic agar medium for detection of extended-spectrum beta-lactamase-producing *Enterobacteriaceae*. *J Clin Microbiol* 2007;45(2):501-5.
- 21 Nilsson P, Alexandersson H, Ripa T. Use of broth enrichment and real-time PCR to exclude the presence of methicillin-resistant *Staphylococcus aureus* in clinical samples: a sensitive screening approach. *Clin Microbiol Infect* 2005;11(12):1027-34.
- 22 Carattoli A, Bertini A, Villa L, Falbo V, Hopkins KL, Threlfall EJ. Identification of plasmids by PCR-based replicon typing. *J Microbiol Methods* 2005;63(3):219-28.
- 23 Skippen I, Shemko M, Turton J, Kaufmann ME, Palmer C, Shetty N. Epidemiology of infections caused by extended-spectrum beta-lactamase-producing *Escherichia coli* and *Klebsiella* spp.: a nested case-control study from a tertiary hospital in London. *J Hosp Infect* 2006;64(2):115-23.
- 24 Kim YK, Pai H, Lee HJ, Park SE, Choi EH, Kim J, et al. Bloodstream infections by extended-spectrum beta-lactamase-producing *Escherichia coli* and *Klebsiella pneumoniae* in children: epidemiology and clinical outcome. *Antimicrob Agents Chemother* 2002;46(5):1481-91.
- 25 Pena C, Pujol M, Ricart A, Ardanuy C, Ayats J, Linares J, et al. Risk factors for faecal carriage of *Klebsiella pneumoniae* producing extended spectrum beta-lactamase (ESBL-KP) in the intensive care unit. *J Hosp Infect* 1997;35(1):9-16.
- 26 Wiener J, Quinn JP, Bradford PA, Goering RV, Nathan C, Bush K, et al. Multiple antibiotic-resistant *Klebsiella* and *Escherichia coli* in nursing homes. *Jama* 1999;281(6):517-23.
- 27 Kang CI, Kim SH, Park WB, Lee KD, Kim HB, Kim EC, et al. Bloodstream infections due to extended-spectrum beta-lactamase-producing *Escherichia coli* and *Klebsiella pneumoniae*: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy. *Antimicrob Agents Chemother* 2004;48(12):4574-81.
- 28 Rodriguez-Bano J, Navarro MD, Romero L, Muniain MA, Perea EJ, Perez-Cano R, et al. Clinical and molecular epidemiology of extended-spectrum beta-lactamase-producing *Escherichia coli* as a

cause of nosocomial infection or colonization: implications for control. *Clin Infect Dis* 2006;42(1):37-45.

29 Martinez JA, Aguilar J, Almela M, Marco F, Soriano A, Lopez F, et al. Prior use of carbapenems may be a significant risk factor for extended-spectrum beta-lactamase-producing *Escherichia coli* or *Klebsiella* spp. in patients with bacteraemia. *J Antimicrob Chemother* 2006;58(5):1082-5.

30 Bradford PA, Urban C, Jaiswal A, Mariano N, Rasmussen BA, Projan SJ, et al. SHV-7, a novel cefotaxime-hydrolyzing beta-lactamase, identified in *Escherichia coli* isolates from hospitalized nursing home patients. *Antimicrob Agents Chemother* 1995;39(4):899-905.

31 Qavi A, Segal-Maurer S, Mariano N, Urban C, Rosenberg C, Burns J, et al. Increased mortality associated with a clonal outbreak of ceftazidime-resistant *Klebsiella pneumoniae*: a case-control study. *Infect Control Hosp Epidemiol* 2005;26(1):63-8.

32 Lee SO, Lee ES, Park SY, Kim SY, Seo YH, Cho YK. Reduced use of third-generation cephalosporins decreases the acquisition of extended-spectrum beta-lactamase-producing *Klebsiella pneumoniae*. *Infect Control Hosp Epidemiol* 2004;25(10):832-7.

33 Meyer KS, Urban C, Eagan JA, Berger BJ, Rahal JJ. Nosocomial outbreak of *Klebsiella* infection resistant to late-generation cephalosporins. *Ann Intern Med* 1993;119(5):353-8.

34 Rahal JJ, Urban C, Horn D, Freeman K, Segal-Maurer S, Maurer J, et al. Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial *Klebsiella*. *Jama* 1998;280(14):1233-7.

35 Patterson JE, Hardin TC, Kelly CA, Garcia RC, Jorgensen JH. Association of antibiotic utilization measures and control of multiple-drug resistance in *Klebsiella pneumoniae*. *Infect Control Hosp Epidemiol* 2000;21(7):455-8.

36 Colodner R, Rock W, Chazan B, Keller N, Guy N, Sakran W, et al. Risk factors for the development of extended-spectrum beta-lactamase-producing bacteria in nonhospitalized patients. *Eur J Clin Microbiol Infect Dis* 2004;23(3):163-7.

37 Calbo E, Romani V, Xercavins M, Gomez L, Vidal CG, Quintana S, et al. Risk factors for community-onset urinary tract infections due to *Escherichia coli* harbouring extended-spectrum beta-lactamases. *J Antimicrob Chemother* 2006;57(4):780-3.

38 Schwaber MJ, Carmeli Y. Mortality and Delay in Effective Therapy Associated with Extended-Spectrum β -Lactamase (ESBL)-Production in *Enterobacteriaceae* bacteremia: a Systematic Review and Meta-Analysis. *J Antimicrob Chemother* 2007;60(5):913-20.

39 Lautenbach E, Patel JB, Bilker WB, Edelstein PH, Fishman NO. Extended spectrum beta-lactamase-producing *Escherichia coli* and *Klebsiella pneumoniae*: risk factors for infection and impact of resistance on outcomes. *Clin Infect Dis* 2001;32(8):1162-71.

40 Kim BN, Woo JH, Kim MN, Ryu J, Kim YS. Clinical implications of extended-spectrum beta-lactamase-producing *Klebsiella pneumoniae* bacteraemia. *J Hosp Infect* 2002;52(2):99-106.

41 The Brooklyn Antibiotic Resistance Task Force. The cost of antibiotic resistance: effect of resistance among *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Acinetobacter baumannii*, and *Pseudomonas aeruginosa* on length of hospital stay. *Infect Control Hosp Epidemiol* 2002;23(2):106-8.

- 42 Schwaber MJ, Navon-Venezia S, Kaye KS, Ben-Ami R, Schwartz D, Carmeli Y. Clinical and economic impact of bacteremia with extended- spectrum-betalactamase- producing *Enterobacteriaceae*. *Antimicrob Agents Chemother* 2006;50(4):1257-62.
- 43 Lee SY, Kotapati S, Kuti JL, Nightingale CH, Nicolau DP. Impact of extendedspectrum beta-lactamase-producing *Escherichia coli* and *Klebsiella* species on clinical outcomes and hospital costs: a matched cohort study. *Infect Control Hosp Epidemiol* 2006;27(11):1226-32.
- 44 Tumbarello M, Spanu T, Sanguinetti M, Citton R, Montuori E, Leone F, et al. Bloodstream infections caused by extended-spectrum-beta-lactamase-producing *Klebsiella pneumoniae*: risk factors, molecular epidemiology, and clinical outcome. *Antimicrob Agents Chemother* 2006;50(2):498-504.
- 45 Zaoutis TE, Goyal M, Chu JH, Coffin SE, Bell LM, Nachamkin I, et al. Risk factors for and outcomes of bloodstream infection caused by extendedspectrum beta-lactamase-producing *Escherichia coli* and *Klebsiella* species in children. *Pediatrics* 2005;115(4):942-9.
- 46 Lucet JC, Decre D, Fichelle A, Joly-Guillou ML, Pernet M, Deblangy C, et al. Control of a prolonged outbreak of extended-spectrum beta-lactamaseproducing *enterobacteriaceae* in a university hospital. *Clin Infect Dis* 1999;29(6):1411-8.
- 47 Albertini MT, Benoit C, Berardi L, Berrouane Y, Boisivon A, Cahen P, et al. Surveillance of methicillin-resistant *Staphylococcus aureus* (MRSA) and *Enterobacteriaceae* producing extended-spectrum beta-lactamase (ESBLE) in Northern France: a five-year multicentre incidence study. *J Hosp Infect* 2002;52(2):107-13.
- 48 French GL, Shannon KP, Simmons N. Hospital outbreak of *Klebsiella pneumoniae* resistant to broad-spectrum cephalosporins and beta-lactam-beta-lactamase inhibitor combinations by hyperproduction of SHV-5 beta-lactamase. *J Clin Microbiol* 1996;34(2):358-63.
- 49 Paterson DL, Singh N, Rihs JD, Squier C, Rihs BL, Muder RR. Control of an outbreak of infection due to extended-spectrum beta-lactamaseproducing *Escherichia coli* in a liver transplantation unit. *Clin Infect Dis* 2001;33(1):126-8.
- 50 Shannon K, Fung K, Stapleton P, Anthony R, Power E, French G. A hospital outbreak of extended-spectrum beta-lactamase-producing *Klebsiella pneumoniae* investigated by RAPD typing and analysis of the genetics and mechanisms of resistance. *J Hosp Infect* 1998;39(4):291-300.
- 51 Bantar C, Vesco E, Heft C, Salamone F, Krayeski M, Gomez H, et al. Replacement of broad-spectrum cephalosporins by piperacillin-tazobactam: impact on sustained high rates of bacterial resistance. *Antimicrob Agents Chemother* 2004;48(2):392-5.
- 52 Lipworth AD, Hyle EP, Fishman NO, Nachamkin I, Bilker WB, Marr AM, et al. Limiting the emergence of extended-spectrum Beta-lactamase-producing *enterobacteriaceae*: influence of patient population characteristics on the response to antimicrobial formulary interventions. *Infect Control Hosp Epidemiol* 2006;27(3):279-86.
- 53 Rice LB, Willey SH, Papanicolaou GA, Medeiros AA, Eliopoulos GM, Moellering RC, Jr., et al. Outbreak of ceftazidime resistance caused by extendedspectrum beta-lactamases at a Massachusetts chronic-care facility. *Antimicrob Agents Chemother* 1990;34(11):2193-9.
- 54 Quale J, Landman D, Saurina G, Atwood E, DiTore V, Patel K. Manipulation of a hospital antimicrobial formulary to control an outbreak of vancomycinresistant enterococci. *Clin Infect Dis* 1996;23(5):1020-5.

- 55 Pena C, Pujol M, Ardanuy C, Ricart A, Pallares R, Linares J, et al. Epidemiology and successful control of a large outbreak due to *Klebsiella pneumoniae* producing extended-spectrum beta-lactamases. *Antimicrob Agents Chemother* 1998;42(1):53-8.
- 56 Ramphal R, Ambrose PG. Extended-spectrum beta-lactamases and clinical outcomes: current data. *Clin Infect Dis* 2006;42 Suppl 4:S164-72.
- 57 Gavin PJ, Suseno MT, Thomson RB, Jr., Gaydos JM, Pierson CL, Halstead DC, et al. Clinical correlation of the CLSI susceptibility breakpoint for piperacillin-tazobactam against extended-spectrum-beta-lactamase-producing *Escherichia coli* and *Klebsiella* species. *Antimicrob Agents Chemother* 2006;50(6):2244-7.
- 58 Teng CP, Chen HH, Chan J, Lye DC. Ertapenem for the treatment of extended spectrum beta-lactamase-producing Gram-negative bacterial infections. *Int J Antimicrob Agents* 2007.
- 59 Pullukcu H, Tasbakan M, Sipahi OR, Yamazhan T, Aydemir S, Ulusoy S. Fosfomycin in the treatment of extended spectrum beta-lactamase-producing *Escherichia coli*-related lower urinary tract infections. *Int J Antimicrob Agents* 2007;29(1):62-5.
- 60 Puerto AS, Fernandez JG, del Castillo Jde D, Pino MJ, Angulo GP. In vitro activity of beta-lactam and non-beta-lactam antibiotics in extended-spectrum beta-lactamase-producing clinical isolates of *Escherichia coli*. *Diagn Microbiol Infect Dis* 2006;54(2):135-9.
- 61 Thomas K, Weinbren MJ, Warner M, Woodford N, Livermore D. Activity of mecillinam against ESBL producers in vitro. *J Antimicrob Chemother* 2006;57(2):367-8.
- 62 Nicolle LE, Mulvey MR. Successful treatment of ctx-m ESBL producing *Escherichia coli* relapsing pyelonephritis with long term pivmecillinam. *Scand J Infect Dis* 2007;39(8):748-9.